BioCentury | Dec 19, 2020
Management Tracks

RNA pioneer Crooke readies to look beyond Ionis

...20 marketed drugs throughout his career, according to Ionis. Among those, recently launched drugs include Tegsedi inotersen...
BioCentury | Sep 15, 2020
Emerging Company Profile

Attralus debuts with $25M series A to tackle systemic amyloidosis

...Spencer Guthrie told BioCentury. Nucleic acid therapies Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Tegsedi inotersen...
BioCentury | Aug 31, 2020
Deals

Three years after spinout, Ionis brings back Akcea in $500M acquisition

...future.”By folding Akcea back into itself, Ionis gains full control of two marketed products: Tegsedi inotersen...
BioCentury | Aug 8, 2020
Product Development

First oral SMA therapy will be delivered to patients’ homes, well placed for virtual launch

...drugs: Duchenne muscular dystrophy therapies Translarna ataluren and Emflaza deflazacort; hereditary transthyretin amyloidosis treatment Tegesdi inotersen...
BioCentury | Nov 13, 2019
Finance

Conjugate company Avidity preps for first dystrophy study with $100M series C

...revealed in September. Akcea gained the approval of two antisense drugs, Waylivra volanesorsen and Tegsedi inotersen...
BioCentury | Oct 30, 2019
Financial News

Pfizer surprises Street with Vyndaqel sales, uptake

...Agreement to Differ ”). Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Akcea Therapeutics Inc. (NASDAQ:AKCA) market Tegsedi inotersen...
BioCentury | Oct 7, 2019
Company News

Amid management shakeup, Akcea strikes latest antisense deal

...30. The company reported $10 million in 2Q19 sales of its first approved drug, Tegsedi inotersen...
BioCentury | Sep 24, 2019
Company News

Unexpected shakeup at Akcea comes amid drug launches

...“ Ionis Lipid Spinout ”). In March 2018, Ionis also granted Akcea rights to Tegsedi inotersen...
...Akcea. Jonathan Block, Associate Editor IONIS-APOCIIIRx, Waylivra, volanesorsen (ISIS 304801, isis-apociiirx, APOC-III antisense inhibitor) Tegsedi, inotersen (IONIS-TTRRx, gsk2998728, isis-ttrrx) Onpattro...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...$18.0 46% Akcea Therapeutics, Inc. (NASDAQ: AKCA) Spun out of Ionis Pharmaceuticals Inc. (NASDAQ:IONS) Tegsedi inotersen...
BioCentury | May 6, 2019
Company News

Pfizer's small molecule tafamidis approved for TTR amyloid cardiomyopathy

...associated with hereditary TTR-mediated amyloidosis (hATTR): Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Tegsedi inotersen...
...gained $0.13 to $26.14. Mary Romeo, Staff Writer Onpattro, patisiran (ALN-TTR02, GENZ438027, GZ438027, SAR438027) Tegsedi, inotersen (IONIS-TTRRx, gsk2998728, isis-ttrrx) Vyndaqel...
Items per page:
1 - 10 of 87